| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2003;107:2949.)
© 2003 American Heart Association, Inc.
Clinical Investigation and Reports |
From the Clinical Research Center, Helios Klinikum-Berlin, Franz Volhard Clinic, Medical Faculty of the Charité, Humboldt-University, Berlin (J.T., C.S., E.S., A.M.S., F.C.L., J.J.), and the Department of Psychiatry, Johannes Gutenberg University, Mainz (S.H.), Germany; and the Autonomic Dysfunction Service, Vanderbilt University, Nashville, Tenn (A.D.).
Correspondence to Jens Jordan, MD, Clinical Research Center, Haus 129, Franz-Volhard-Clinic, Humboldt University, Wiltbergstraße 50, 13125 Berlin, Germany. E-mail jordan{at}fvk-berlin.de
Background Norepinephrine transporter (NET) inhibition increases the responsiveness to vasoactive medications and attenuates the response to sympathetic stimuli. The phenomenon may be a result of impaired regulation of sympathetic vasomotor tone.
Methods and Results We studied the effects of the selective NET blocker reboxetine and placebo on baroreflex control of heart rate (HR) and sympathetic traffic in a randomized, double-blind, crossover manner in healthy subjects. Subjects ingested 8 mg reboxetine or placebo 12 hours and 1 hour before testing. ECGs were measured for HR, brachial and finger blood pressure (BP), and muscle sympathetic nerve activity (MSNA). Sympathetic and parasympathetic baroreflex slopes were determined by use of incremental phenylephrine and nitroprusside infusions. The dose to reach BP changes of 12.5 mm Hg was significantly lower during NET inhibition (0.25 versus 0.64 µg · kg-1 · min-1 phenylephrine and 0.40 versus 1.10 µg · kg-1 · min-1 nitroprusside, P<0.01). Baroreflex control of HR was similar (16 ms/mm Hg with placebo versus 14 ms/mm Hg with reboxetine) but reset to higher BP values. MSNA and sympathetically mediated low-frequency BP oscillations were profoundly reduced at baseline and failed to increase sufficiently during nitroprusside infusion. Reboxetine attenuated BP and MSNA responses to cold pressor testing.
Conclusions NET inhibition profoundly and selectively reduces baroreflex control of sympathetic vasomotor tone and attenuates the responsiveness to sympathetic stimuli. The reduction in baroreflex buffering increases the sensitivity to vasoactive medications. Therefore, our findings represent a novel mechanism for drug interactions.
Key Words: nervous system, autonomic baroreflex antidepressive agents receptors, adrenergic, alpha catecholamines
This article has been cited by other articles:
![]() |
J. Tank, K. Heusser, A. Diedrich, D. Hering, F. C. Luft, A. Busjahn, K. Narkiewicz, and J. Jordan Influences of Gender on the Interaction between Sympathetic Nerve Traffic and Central Adiposity J. Clin. Endocrinol. Metab., December 1, 2008; 93(12): 4974 - 4978. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Moldovanova, C. Schroeder, G. Jacob, C. Hiemke, A. Diedrich, F. C. Luft, and J. Jordan Hormonal Influences on Cardiovascular Norepinephrine Transporter Responses in Healthy Women Hypertension, April 1, 2008; 51(4): 1203 - 1209. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Strempel, C. Schroeder, R. Hemmersbach, A. Boese, J. Tank, A. Diedrich, M. Heer, F. C. Luft, and J. Jordan Norepinephrine transporter inhibition alters the hemodynamic response to hypergravitation J Appl Physiol, March 1, 2008; 104(3): 756 - 760. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Torp-Pedersen, I. Caterson, W. Coutinho, N. Finer, L. Van Gaal, A. Maggioni, A. Sharma, W. Brisco, R. Deaton, G. Shepherd, et al. Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial Eur. Heart J., December 1, 2007; 28(23): 2915 - 2923. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Tank, K. Heusser, A. Diedrich, R. J. Brychta, F. C. Luft, and J. Jordan Yohimbine Attenuates Baroreflex-Mediated Bradycardia in Humans Hypertension, November 1, 2007; 50(5): 899 - 903. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Shibao, S. R. Raj, A. Gamboa, A. Diedrich, L. Choi, B. K. Black, D. Robertson, and I. Biaggioni Norepinephrine Transporter Blockade With Atomoxetine Induces Hypertension in Patients With Impaired Autonomic Function Hypertension, July 1, 2007; 50(1): 47 - 53. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Heusser, S. Engeli, J. Tank, A. Diedrich, S. Wiesner, J. Janke, F. C. Luft, and J. Jordan Sympathetic Vasomotor Tone Determines Blood Pressure Response to Long-Term Sibutramine Treatment J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1560 - 1563. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Schroeder, A. L. Birkenfeld, A. F. Mayer, J. Tank, A. Diedrich, F. C. Luft, and J. Jordan Norepinephrine Transporter Inhibition Prevents Tilt-Induced Pre-Syncope J. Am. Coll. Cardiol., August 1, 2006; 48(3): 516 - 522. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. F. Mayer, C. Schroeder, K. Heusser, J. Tank, A. Diedrich, R. E. Schmieder, F. C. Luft, and J. Jordan Influences of Norepinephrine Transporter Function on the Distribution of Sympathetic Activity in Humans Hypertension, July 1, 2006; 48(1): 120 - 126. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Sharma Does pharmacologically induced weight loss improve cardiovascular outcome? Sibutramine pharmacology and the cardiovascular system Eur. Heart J. Suppl., November 1, 2005; 7(suppl_L): L39 - L43. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Schroeder, S. Vernino, A. L. Birkenfeld, J. Tank, K. Heusser, A. Lipp, T. Benter, C. Lindschau, R. Kettritz, F. C. Luft, et al. Plasma exchange for primary autoimmune autonomic failure. N. Engl. J. Med., October 13, 2005; 353(15): 1585 - 1590. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Tank, A. Diedrich, E. Szczech, F. C. Luft, and J. Jordan Baroreflex Regulation of Heart Rate and Sympathetic Vasomotor Tone in Women and Men Hypertension, June 1, 2005; 45(6): 1159 - 1164. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. R. Keller, A. Diedrich, M. Appalsamy, S. Tuntrakool, S. Lonce, C. Finney, M. G. Caron, and D. Robertson Norepinephrine Transporter-Deficient Mice Exhibit Excessive Tachycardia and Elevated Blood Pressure With Wakefulness and Activity Circulation, September 7, 2004; 110(10): 1191 - 1196. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Kawada, T. Miyamoto, K. Uemura, K. Kashihara, A. Kamiya, M. Sugimachi, and K. Sunagawa Effects of neuronal norepinephrine uptake blockade on baroreflex neural and peripheral arc transfer characteristics Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2004; 286(6): R1110 - R1120. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Schroeder, F. Adams, M. Boschmann, J. Tank, S. Haertter, A. Diedrich, I. Biaggioni, F. C. Luft, and J. Jordan Phenotypical evidence for a gender difference in cardiac norepinephrine transporter function Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2004; 286(5): R851 - R856. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Tank, A. Diedrich, E. Szczech, F. C. Luft, and J. Jordan {alpha}-2 Adrenergic Transmission and Human Baroreflex Regulation Hypertension, May 1, 2004; 43(5): 1035 - 1041. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Woolard, T. Bennett, W. R. Dunn, D. J. Heal, S. Aspley, and S. M. Gardiner Acute Cardiovascular Effects of Sibutramine in Conscious Rats J. Pharmacol. Exp. Ther., March 1, 2004; 308(3): 1102 - 1110. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2003 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |